MedTrace Logo

Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis

NCT00647348 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2019-12-12

Study results available
· View outcomes & findings →

Summary

To determine whether simvastatin at a dose of 80mg can reduce the rate of whole brain atrophy, as measured by MRI, over a 2-year time-period when compared to placebo.

Conditions

  • Secondary Progressive Multiple Sclerosis

Interventions

DRUG

Simvastatin

80mg simvastatin oral once daily for 24 months

DRUG

Placebo

Oral placebo tablet once daily for 24 months

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Jeremy Chataway, MB BCh, PhD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00647348 on ClinicalTrials.gov